Medicaid

Exclusive By Rachel Cohrs and Lev Facher

Top Senate Republican holds up Biden’s CMS nominee over Texas Medicaid waiver

Pharmalot By Ed Silverman

Federal agency says pharma should pay higher Medicaid rebates if certain trials aren’t finished on time

Pharmalot By Ed Silverman

Tennessee to become the first state to run a closed Medicaid drug formulary

Health Tech By Casey Ross

Health tech’s newest unicorn is running toward Medicaid patients long marginalized in medicine

First Opinion By Michael Hochman and Michelle Levander

Create a scorecard to help make safety-net providers accountable to patients and the public

First Opinion By Eric Letsinger and Alison Rein

Invest in community-based organizations to put health dollars where they are really needed

STAT+ Conversations By Casey Ross

‘I can’t imagine going back’: Medicare leader calls for expanded telehealth access after Covid-19

Pharmalot By Ed Silverman

Mallinckrodt loses a court case and is on the hook for $650 million in overdue Medicaid rebates

First Opinion By Eric Schneider

Super Tuesday results suggest that Americans ‘aren’t looking for big structural changes’ in health care

First Opinion By Wendy E. Parmet

Trump’s immigration policies will make the coronavirus pandemic worse

Pharmalot By Ed Silverman

Justice Department sues Mallinckrodt over ‘hundreds of millions of dollars’ in Medicaid rebates

Pharmalot By Ed Silverman

PBMs favor their own pharmacies in the Florida Medicaid program

Pharmalot By Ed Silverman

U.S. officials will let Novartis pay expenses for some Kymriah patients who must travel for treatment

First Opinion By Maria Kefalas

Medicaid covers sick or dying children. But it takes ‘going to battle’ to get it

First Opinion By Ira Byock and Eric Walsh

Hopewell House hospice has closed. You should care about that

Politics By Priyanka Dayal McCluskey — Boston Globe and Matt Stout — Boston Globe

Mass. governor — and one-time insurance executive — eyes a legacy-defining revamp of state’s health care

Pharmalot By Ed Silverman

Pharmalittle: Five companies offer $50 billion deal to settle opioid suits; FDA approves record number of generics

Pharmalot By Ed Silverman

Most state Medicaid programs continue to restrict access to hepatitis C medicines

Pharmalot By Ed Silverman

A murky approach to tracking 340B drugs and Medicaid may yield double discounts in some states

Pharmalot By Ed Silverman

Avanir to pay $116 million to settle bribery charges, while two docs and former sales reps are indicted

Pharmalot By Ed Silverman

Mylan pays $30 million to settle charges of misleading investors over probe into EpiPen Medicaid rebates

Pharmalot By Ed Silverman

Few Americans took obesity drugs thanks to doctor doubts and spotty insurance

First Opinion By Chuck Grassley

Grassley: For Medicaid, greater transparency will open the door to better value and outcomes

Pharmalot By Ed Silverman

Massachusetts lawmakers approve compromise bill to lower Medicaid drug spending

Pharmalot By Ed Silverman

Pharmalittle: Trump abandons rebate rule; biotechs fume at Mass. governor’s plan to lower drug prices